Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

OriginCell Posts Positive Data from Trial of GPC3 CAR-T for HCC

publication date: Jun 7, 2021

Shanghai OriginCell Therapeutics presented positive data from an on-going trial of its GPC3 CAR-T cell therapy in patients with relapsed/refractory hepatocellular carcinoma (HCC). Ori-CAR-001 produced a 44.4% objective response rate and a 77.8% disease control rate in the eleven enrolled patients, all of whom had received two previous treatments. OriginCell has built four technology platforms, including an antibody development platform, a high-memory CAR T technology platform, a cell expansion platform and a universal CAR-T platform. OriginCell is aiming Ori-CAR-001 at solid tumor cancers. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital